![](\"https:\/\/mms.businesswire.com\/media\/20260701026045\/en\/2842815\/5\/Momentum_Full_Color_Logo.jpg\"){kind=logo}
<\/a><\/a>\nThe investment will provide Momentum with strategic resources and capital to accelerate its growth strategy and pursue strategic acquisitions that support the Company\u2019s mission to address one of the most persistent challenges facing pharmaceutical and biotechnology manufacturers, patients, and providers: enabling patients to start and stay on the specialty therapies they need.<\/p>
\n\u201cThis is a defining moment for Momentum and the clients, patients, and providers we serve,\u201d said Andi Heslin Smiley, President and CEO of Momentum Life Sciences. \u201cPartnering with Parthenon provides us with additional resources and an aligned strategic partner to continue to strengthen our platform, deepen our capabilities, and take on a greater role in creating better experiences and outcomes for clients, patients, and providers, which sits at the heart of everything we do.\u201d<\/p>
\nDan Killeen, a Partner at Parthenon, said, \u201cTherapy adoption, initiation, and adherence are some of the most acute and underserved challenges facing life sciences organizations today. As therapies have become more specialized, navigating behavioral, access, financial, and operational barriers to treatment has become increasingly important. Momentum has built a differentiated platform to address these pain points, and we see a compelling opportunity to expand the Company's presence across the commercialization ecosystem.\u201d<\/p>
\nPatrick Hunt, a Principal at Parthenon, continued, \u201cMomentum has built something rare: a deeply trusted clinical and human-centered platform that has proven to not only improve the patient and provider experience but also drive tangible and consistent commercial impacts for clients. We see tremendous potential in continuing the Company\u2019s mission and expanding the role Momentum plays in supporting life sciences organizations, providers, and patients along the specialty therapy journey. We are excited to support Andi and the team as Momentum enters this next chapter of growth.\u201d<\/p>
\nWilliam Blair served as financial advisor to Momentum, and Cooley served as legal counsel. Kirkland & Ellis served as legal counsel to Parthenon.<\/p>
\nAbout Momentum Life Sciences\n \nAbout Parthenon Capital\n